140 related articles for article (PubMed ID: 12761334)
1. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
Chinje EC; Cowen RL; Feng J; Sharma SP; Wind NS; Harris AL; Stratford IJ
Mol Pharmacol; 2003 Jun; 63(6):1248-55. PubMed ID: 12761334
[TBL] [Abstract][Full Text] [Related]
2. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
Saunders MP; Patterson AV; Chinje EC; Harris AL; Stratford IJ
Br J Cancer; 2000 Feb; 82(3):651-6. PubMed ID: 10682679
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents.
Garner AP; Paine MJ; Rodriguez-Crespo I; Chinje EC; Ortiz De Montellano P; Stratford IJ; Tew DG; Wolf CR
Cancer Res; 1999 Apr; 59(8):1929-34. PubMed ID: 10213502
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of tirapazamine by multiple reductases in the nucleus.
Delahoussaye YM; Evans JW; Brown JM
Biochem Pharmacol; 2001 Nov; 62(9):1201-9. PubMed ID: 11705453
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
[TBL] [Abstract][Full Text] [Related]
6. Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
Guise CP; Abbattista MR; Anderson RF; Li D; Taghipouran R; Tsai A; Lee SJ; Smaill JB; Denny WA; Hay MP; Wilson WR; Hicks KO; Patterson AV
Molecules; 2020 Oct; 25(21):. PubMed ID: 33105798
[TBL] [Abstract][Full Text] [Related]
7. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
Elwell JH; Siim BG; Evans JW; Brown JM
Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
[TBL] [Abstract][Full Text] [Related]
8. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
[TBL] [Abstract][Full Text] [Related]
9. Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
Chinje EC; Patterson AV; Saunders MP; Lockyer SD; Harris AL; Stratford IJ
Br J Cancer; 1999 Dec; 81(7):1127-33. PubMed ID: 10584872
[TBL] [Abstract][Full Text] [Related]
10. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.
Delahoussaye YM; Hay MP; Pruijn FB; Denny WA; Brown JM
Biochem Pharmacol; 2003 Jun; 65(11):1807-15. PubMed ID: 12781332
[TBL] [Abstract][Full Text] [Related]
11. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes.
Evans JW; Yudoh K; Delahoussaye YM; Brown JM
Cancer Res; 1998 May; 58(10):2098-101. PubMed ID: 9605751
[TBL] [Abstract][Full Text] [Related]
12. Suppression of hypoxia-inducible factor 1α (HIF-1α) by tirapazamine is dependent on eIF2α phosphorylation rather than the mTORC1/4E-BP1 pathway.
Zhang J; Cao J; Weng Q; Wu R; Yan Y; Jing H; Zhu H; He Q; Yang B
PLoS One; 2010 Nov; 5(11):e13910. PubMed ID: 21085474
[TBL] [Abstract][Full Text] [Related]
13. Exploiting the Inherent Photophysical Properties of the Major Tirapazamine Metabolite in the Development of Profluorescent Substrates for Enzymes That Catalyze the Bioreductive Activation of Hypoxia-Selective Anticancer Prodrugs.
Shen X; Laber CH; Sarkar U; Galazzi F; Johnson KM; Mahieu NG; Hillebrand R; Fuchs-Knotts T; Barnes CL; Baker GA; Gates KS
J Org Chem; 2018 Mar; 83(6):3126-3131. PubMed ID: 29461834
[TBL] [Abstract][Full Text] [Related]
14. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.
Xu P; Huang JM; Ren Y; Zha X; Deng BF; Wu JH; Lang JY
Chin J Cancer; 2010 Feb; 29(2):126-30. PubMed ID: 20109337
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation.
Hong B; Lui VW; Hui EP; Ng MH; Cheng SH; Sung FL; Tsang CM; Tsao SW; Chan AT
Invest New Drugs; 2011 Jun; 29(3):401-10. PubMed ID: 20013349
[TBL] [Abstract][Full Text] [Related]
16. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
17. Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).
Mehibel M; Singh S; Chinje EC; Cowen RL; Stratford IJ
Mol Cancer Ther; 2009 May; 8(5):1261-9. PubMed ID: 19435866
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of DNA replication by tirapazamine.
Peters KB; Wang H; Brown JM; Iliakis G
Cancer Res; 2001 Jul; 61(14):5425-31. PubMed ID: 11454687
[TBL] [Abstract][Full Text] [Related]
19. Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxin.
Baker JH; Kyle AH; Bartels KL; Methot SP; Flanagan EJ; Balbirnie A; Cran JD; Minchinton AI
PLoS One; 2013; 8(10):e76832. PubMed ID: 24204680
[TBL] [Abstract][Full Text] [Related]
20. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.
Hicks KO; Fleming Y; Siim BG; Koch CJ; Wilson WR
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):641-9. PubMed ID: 9806526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]